Malignant thoracic epithelioid vascular tumors are an uncommon and heterogenous group of tumors that include lowgrade to intermediate-grade epithelioid hemangioendothelioma (EHE) and high-grade epithelioid angiosarcoma (EAS). We examine the morphologic and immunohistochemical features of 52 malignant epithelioid vascular tumors (10 low-grade EHE, 29 intermediate-grade EHE, and 13 EAS) involving the thorax (lung, pleura, mediastinum, heart, great vessels) including cases with exclusively thoracic disease (35) and with multiorgan disease including the thorax (17). Intermediate-grade EHE differs from low-grade EHE by the presence of necrosis, increased mitotic activity, and increased atypia. Morphologic features such as intranuclear inclusions, intracytoplasmic vacuoles, and stromal changes (chondroid, myxoid, or hyalinized stroma) are seen more frequently in EHE, whereas blood lakes, proliferation of slit-like vessels, and prominent nucleoli favor EAS. Fluorescence in situ hybridization analysis showed CAMTA1-WWTR1 fusions in 4/7 low-grade and 23/23 intermediate-grade EHE (P < 0.001). In EAS, CAMTA1 rearrangement was negative in all cases, whereas a WWTR1 complex abnormality was found in 1/5 cases (P < 0.001). This offers an objective means of differentiating intermediate-grade EHE from EAS, especially on limited biopsies. All cases show expression of at least 1 vascular marker, which allows differentiation from primary thoracic epithelial malignancies, although keratin expression is a potential pitfall with 29% of EHE and 25% of EAS showing keratin expression. Survival analysis shows that higher tumor grade for all tumors (P = 0.026) as well as lung and pleural tumors only (P = 0.010) and the presence of pleural involvement in lung and/ or pleural tumors (P = 0.042) correlate with poor prognosis.
of diseases that includes epithelioid hemangioma, a benign neoplasm; epithelioid hemangioendothelioma (EHE), a low-grade to intermediate-grade malignancy; and epithelioid angiosarcoma (EAS), a high-grade malignancy. 1, 2 Weiss and Enzinger 3 first described EHE as a vascular tumor with clinical and morphologic features intermediate between hemangioma and angiosarcoma. Because of marked variability in clinical outcome and morphologic features, the World Health Organization of soft tissue tumors proposed the dichotomy of EHE into 2 histologic grades: classic (low-grade) and malignant (intermediate-grade) EHE. 4 However, this subclassification has not been validated in other anatomic sites. Although certain morphologic features allow to distinguish EHE from EH and EAS, the diagnosis can be challenging because of considerable morphologic overlap at both ends of the spectrum, particularly on small biopsies. Recent studies have identified recurrent genetic alterations, such as the WWTR1-CAMTA1 fusion in EHE, but not in other vascular tumors. 5, 6 In this study, we sought to evaluate a large cohort of malignant epithelioid vascular tumors occurring in the thorax for their morphologic features, immunophenotype, clinical course, and WWTR1 and CAMTA1 gene rearrangements.
MATERIALS AND METHODS

Clinical and Pathologic Features
Fifty-two cases of malignant epithelioid vascular tumors (39 EHE and 13 EAS) with thoracic involvement from our institution and the personal consults of the senior authors (W.D.T., C.R.A.) were included in our study. The cytologic and architectural features of each case were reviewed, and tumors were classified using criteria established in the soft tissue literature and include 10 cases of low-grade EHE (G1), 29 cases of intermediategrade EHE (G2), and 13 cases of EAS (G3). Cases with either exclusive thoracic disease (35) or multiorgan disease including thoracic involvement (17) were selected in the study. The main sites of involvement for the exclusively thoracic tumors were lung (13) , pleura (17) , and mediastinum (5) . The gross anatomic features, clinical history, and clinical outcome were obtained from review of consult letters, pathology reports, clinical notes, and public records including the Social Security Death Index and through conversations with pathologists and/or clinicians from the submitting institutions. Statistical analyses with cross-tables and w 2 were performed using SPSS v 22.0. Survival analysis was performed using the Kaplan-Meier method and log rank for significance. The time of survival was calculated using Kaplan-Meier estimates from the date of initial diagnosis to the date of death or last clinical follow-up. The study was approved by the Institutional Review Board 02-060.
Immunohistochemistry
Immunohistochemical stains submitted from outside institutions were reviewed. On in-house cases and outside cases in which further immunohistochemical workup was needed, we performed immunohistochemistry in our laboratory for CD31 and ERG (Ventana; prediluted) to confirm vascular differentiation and immunohistochemistry for AE1/AE3 (Dako; 1:400), CAM5.2 (Becton Dickinson; 1:50), and CK18 (Dako; 1:1000) as part of an initial workup when vascular differentiation was not evident.
Fluorescence In Situ Hybridization Studies
Fluorescence in situ hybridization (FISH) on interphase nuclei from paraffin-embedded 4-mm-thick sections was performed applying custom probes using bacterial artificial chromosomes (BAC) for WWTR1, CAMTA1, and TFE3. BAC clones were chosen according to UCSC genome browser (http://genome.ucsc.edu). 5, 7 The BAC clones were obtained from BACPAC sources of Children's Hospital of Oakland Research Institute (CHORI) (Oakland, CA) (http://bacpac.chori.org). DNA from individual BACs was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with DAPI in an antifade solution, as previously described. 8 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems). A positive score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with incomplete set of signals were excluded.
RESULTS
Clinical and Pathologic Features Demographics
There were 36 men and 16 women included in the study, ranging in age from 22 to 84 years (mean 56.4 y) ( Table 1 ). It is noteworthy that a female predominance was noted in G1 tumors, whereas a male predominance was present in G2 and G3 tumors when examining either all thoracic sites (P < 0.001) or tumors occurring only in the lung and pleura (P = 0.021). Patients with EAS were significantly older than those with EHE, regardless of whether it occurred at any thoracic site (P = 0.008) or only in the lung and pleura (P = 0.028).
Gross Features
Because the majority of cases in our study were personal consults and/or small biopsies, the gross extent of disease was assessed by reviewing outside pathology and radiology reports. Also recorded was the multiorgan involvement, the primary site of the tumor, multifocal involvement within the lungs, and the degree of pleural involvement (mass, multiple nodules, or diffuse thickening). When a dominant mass was present, the size of this mass was noted.
Histologic Features
EHE in the lung typically showed micropolypoid protrusion within alveolar spaces at the periphery of tumor nodules ( Fig. 1 ). Tumors presenting in the pleura showed marked thickening of the pleura by tumor frequently with infiltration of adjacent adipose tissue (Fig. 1B) . The EHEs were subdivided into 2 histologic grades, G1 and G2, using criteria established in the soft tissue EHE on the basis of increased mitotic rate (P = 0.003, with counts >1/2 mm 2 ), the presence of necrosis (P < 0.001), and moderate to marked nuclear pleomorphism (P = 0.031) 4 (Fig. 2) . No mitoses were seen in low-grade EHE, whereas the mean was 2/2 mm 2 (range, 0 to 9) in intermediate-grade EHE and 5/2 mm 2 (range, 1 to 12) in EAS. The overlap in mitotic counts between intermediate-grade EHE and EAS made it difficult to establish a mitotic threshold for separating these tumors. The cytologic features, growth pattern, and the presence/absence of pleural involvement by tumor were assessed. Features suggestive of EHE included intracytoplasmic lumens, nuclear cytoplasmic inclusions, and distinctive extracellular stroma, with chondroid, hyalinized, or myxoid changes ( Table 2 and Fig. 3 ). EAS were classified by default as G3. Histologic features suggestive of EAS included prominent capillary-like vasoformative elements, blood lakes, papillary growth, and prominent nucleoli ( Table 2 and Fig. 4 ). The number of mitotic figures increased significantly with tumor grade, with a mean of <1 mitoses/2 mm 2 (all had <1) for G1 tumors, 2/2 mm 2 (range, 0 to 9) for G2 tumors, and 5/2 mm 2 (range, 1 to 12) for G3 tumors.
Immunohistochemistry
All cases expressed at least 1 vascular marker (Table 3 ). We found CD31 and ERG to be the most reliable markers of vascular differentiation, seen in 96% and 100% of cases, respectively. Expression of keratin was seen in a substantial number of cases of both EHE and EA ( Table 3 ). The mesothelial markers WT1 (0/15 cases) and calretinin (0/21 cases) were not expressed in any tumors, whereas D2-40 expression was seen in over half of tumors (5/9 cases) tested.
FISH Studies for Gene Rearrangements in WWTR1 and CAMTA1
FISH was performed on 35 cases with available material, including 30/39 cases classified morphologically as EHE. Custom break-apart BAC probes for both WWTR1 and CAMTA1 genes were tested on all available cases. Gene rearrangements involving both WWTR1 and CAMTA1 were seen in 3 of 7 G1 tumors tested and 23 of 23 G2 tumors (Table 4 and Fig. 2 ). No CAMTA1 gene rearrangement was seen in any of the 5 EAS tumors tested; however, 1 EAS tumor showed a complex rearrangement involving the WWTR1 gene (Table 4 ). These differences were significant for all tumors in the thorax as well as those involving lung and pleura only ( Table 4 , P < 0.001). All fusion-negative EHEs and the single EAS case with a WWTR1 gene rearrangement were rereviewed and the diagnosis reconfirmed. The CAMTA1-WWTR1-negative EHE cases were subsequently tested for TFE3 gene arrangements by FISH; however, no positive case was identified.
Clinical Course and Follow-up
The most common symptoms at presentation were pleural effusion (39%), chest pain (29%), shortness of breath (16%), hemoptysis (13%), and cough (12%). Two cases were discovered incidentally. Of the 17 cases with multiorgan involvement, 7 had material from multiple sites for histologic examination, and 10 had radiologic evidence of multiorgan involvement.
Survival Analysis
Survival analysis was performed on 51 cases with follow-up information available. One patient with a G1 tumor was lost to follow-up. Histologic grade significantly affected prognosis with G2 and G3 having significantly worse prognosis than G1 tumors. This finding was seen on analyzing either the entire patient cohort (Fig. 5) or cases involving only the lungs and pleura (Fig. 6 ). The 4-year survival for G1, G2, and G3 tumors was 75%, 21%, and 9%, respectively, for all tumors (P = 0.026) and 83%, 22%, and 9%, respectively, for only lung and pleural tumors (P = 0.010). There was no statistical difference in survival when the analysis included only primary thoracic tumors. Microscopic evidence of pleural involvement was a poor prognostic indicator for all tumor grades (P = 0.042, Fig. 7 ) and in EHE alone (P = 0.049). For all tumor grades and for EHE alone, the 3-year survival rate was 46% and 52% when lacking pleural involvement compared with 16% and 24%, respectively, when the pleura was involved. A similar trend was seen in EAS; however, it failed to reach significance. Given that higher-grade tumors have a higher mitotic rate, it was not surprising to find that increased mitotic activity was a poor prognostic indicator for all tumors (P = 0.015) and for those involving only the lung and pleura (P = 0.016). The only clinical symptom that was a significant indicator of poor outcome was hemoptysis (P = 0.001). This may be due to the fact that hemoptysis was seen in 46% of EAS and in only a single case of EHE. There was no difference in survival between those patients with thoracic-only versus those with multifocal disease (P > 0.05) for all tumors, grade 1 and grade 2 EHE. However, for grade 3 EAS, patients with multiorgan disease had a worse 6-month survival (0%) than those with thoracic-only involvement (58%, P = 0.047).
DISCUSSION
The results of our study show that malignant epithelioid vascular tumors involving the thorax can be classified as low-grade EHE, intermediate-grade EHE, and high-grade EAS. This is supported by distinct morphologic features between these 3 entities, our survival data, and the demonstration of a CAMTA1-WWTR1 gene fusion in EHE but not EAS. Our survival data also show that pleural involvement is a poor prognostic indicator. Factors that did not significantly affect prognosis include the presence or absence of extrathoracic disease and tumor size.
In reviewing the histology, features seen significantly more in EHE included intracytoplasmic vacuoles, intranuclear inclusions, and prominent myxoid, hyalinized, or chondroid stroma. In contrast, features Am J Surg Pathol Volume 39, Number 1, January 2015 Thoracic Malignant Epithelioid Vascular Tumors associated with the EAS included vasoformative features with capillary-type vascular spaces, blood lakes, papillary growth, marked nuclear atypia, prominent nucleoli, and increased mitotic rate. In limited small biopsies, the lack of these histologic features may present a diagnostic challenge in differentiating vascular tumors from carcinoma and malignant mesothelioma, which are more frequently encountered in the thorax and often share similar radiologic 9-11 and pathologic findings. [12] [13] [14] Immunohistochemical demonstration of vascular differentiation is crucial in these cases given the similar morphologic features. Keratin expression in epithelioid vascular tumors is a known diagnostic pitfall. 15 Our study showed that 29% of EHE and 25% of EAS that were tested expressed some degree of keratin expression with either pankeratin, CK7, CAM5.2, or CK18 (Fig. 4) . This emphasizes the importance of keeping the differential diagnosis of an epithelioid vascular tumor in mind when diagnosing tumors that in the thorax are often assumed to be carcinomas or mesotheliomas, as these tumors are so much more common than EHE or EAS. Another diagnostic challenge after establishing the vascular differentiation is distinguishing intermediategrade EHE (G2) from EAS (G3) tumors in cases that exhibit increased mitotic activity, necrosis, and atypia but lack overt capillary-like vasoformative elements. Testing for WWTR1-CAMTA1 gene fusion, a recurrent genetic abnormality seen in EHEs across various anatomic sites but absent in EAS, offers an objective mean to distinguish EHE from EAS. In fact all G2 tumors tested demonstrated gene rearrangements in both WWTR1 and CAMTA1, whereas none of EAS analyzed demonstrated this gene fusion. The utility of FISH studies in detecting the WWTR1-CAMTA1 fusion in a small biopsy is confirmed by the demonstration of CAMTA1 and WWTR1 break-apart abnormalities in all 13 EHEs diagnosed on small biopsy material (3 G1 and 10 G2 tumors). Although 1 case of EAS demonstrated a complex abnormality of WWTR1, there was no accompanying CAMTA1 gene rearrangement to suggest a t(1;3) translocation. Although the majority of the G1 tumors showed the WWTR1-CAMTA1 fusions, 3 cases did not. We considered the possibility of a YAP1-TFE3 gene fusion, a finding that has been observed in a subset of EHEs that are negative for WWTR1 and CAMTA1 abnormalities 7 ; however, FISH did not demonstrate a TFE3 gene rearrangement in any of these cases. Lack of cellularity in the specimens was also considered; however, all 3 had adequate tumor cells for FISH studies.
Our survival data show that histologic grade significantly affects prognosis within the malignant epithelioid vascular tumor spectrum, with G1 tumors having a relatively favorable prognosis, G2 tumors a poor prognosis, and G3 tumors the worst prognosis. This suggests that the reported criteria for classifying and grading malignant vascular tumors within soft tissue might be applicable to tumors in the thoracic cavity. Pleural involvement was another poor prognostic indicator for both EHE and EAS together and also for EHE alone. Several other studies have highlighted the poor prognosis for vascular tumors of the pleura. 16, 17 Nine cases in our study presented in unusual locations including mediastinum (7 cases Little data exist on the behavior of superior vena cava tumors because of their extreme rarity. 19, 20 In conclusion malignant epithelioid vascular tumors involving the thorax can be classified as low-grade (G1) to intermediate-grade (G2) EHE and high-grade EAS (G3). We prefer not to use the terms classic and malignant, because all EHE cases are malignant. This concept is supported by our histologic findings, survival data, and demonstration of a CAMTA1-WWTR1 gene fusion in EHE but not in EAS. The presence of CAMTA1-WWTR1 gene fusion in EHE but not EAS suggests that EHE and EAS do not form a histologic continuum, and it is in keeping with 2 genetically distinct neoplasms. As the presence of WWTR1-CAMTA1 fusion is seen in most EHE cases (both low-grade and intermediate-grade tumors), additional genetic abnormalities most likely occur in the G2 subset of tumors to drive their aggressive behavior. FISH analysis for CAMTA1 and WWTR1 gene rearrangements offers an objective way to distinguish EHE and EAS in cases with nuclear atypia, necrosis, or increased mitotic activity that lack the typical histologic hallmarks of EAS. Expression of keratin is problematic and may lead to a misdiagnosis of carcinoma or mesothelioma, which are encountered more frequently in the thorax and may show clinical, radiologic, and morphologic overlap with epithelioid vascular tumors. Careful examination for histologic features suggestive of vascular differentiation (blister cells, intracytoplasmic lumens, vasoformative elements) and immunohistochemistry with vascular markers are helpful in avoiding this pitfall.
